Title |
Mortality and Recurrence Risk in Relation to the Use of Lipid-Lowering Drugs in a Prospective Breast Cancer Patient Cohort
|
---|---|
Published in |
PLOS ONE, September 2013
|
DOI | 10.1371/journal.pone.0075088 |
Pubmed ID | |
Authors |
Stefan Nickels, Alina Vrieling, Petra Seibold, Judith Heinz, Nadia Obi, Dieter Flesch-Janys, Jenny Chang-Claude |
Abstract |
Lipid-lowering drugs are used for the prevention of cardiovascular diseases. Statins are the most commonly used lipid-lowering drugs. Evidence from preclinical and observational studies suggests that statins might improve the prognosis of breast cancer patients. We analyzed data from the German MARIEplus study, a large prospective population-based cohort of patients aged 50 and older, who were diagnosed with breast cancer between 2001 and 2005. For overall mortality, breast-cancer specific mortality, and non-breast-cancer mortality, we included 3189 patients with invasive breast cancer stage I-IV, and for recurrence risk 3024 patients with breast cancer stage I-III. We used Cox proportional hazards models to assess the association with self-reported lipid-lowering drug use at recruitment. We stratified by study region, tumor grade, and estrogen/progesterone receptor status, and adjusted for age, tumor size, nodal status, metastases (stage I-IV only), menopausal hormone treatment, mode of detection, radiotherapy, and smoking. Mortality analyses were additionally adjusted for cardiovascular disease, diabetes mellitus and body-mass index. During a median follow-up of 5.3 years, 404 of 3189 stage I-IV patients died, and 286 deaths were attributed to breast cancer. Self-reported use of lipid-lowering drugs was non-significantly associated with increased non-breast cancer mortality (Hazard ratio (HR) 1.49, 95% confidence interval (CI) 0.88-2.52) and increased overall mortality (HR 1.21, 95% CI 0.87-1.69) whereas no association with breast cancer-specific mortality was found (HR 1.04, 0.67-1.60). Restricted to stage I-III breast cancer patients, 387 recurrences occurred during a median follow-up of 5.4 years. We found lipid-lowering drug use to be non-significantly associated with a reduced risk of recurrence (HR 0.83, 95% CI 0.54-1.24) and of breast cancer-specific mortality (HR 0.89, 95% CI 0.52-1.49). Although compatible with previous findings of an improved prognosis associated with statin use, our results do not provide clear supportive evidence for an association with lipid-lowering drug use due to imprecise estimates. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 1% |
Netherlands | 1 | 1% |
Portugal | 1 | 1% |
Unknown | 71 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 15 | 20% |
Student > Master | 11 | 15% |
Student > Bachelor | 10 | 14% |
Researcher | 8 | 11% |
Other | 3 | 4% |
Other | 7 | 9% |
Unknown | 20 | 27% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 35 | 47% |
Nursing and Health Professions | 4 | 5% |
Biochemistry, Genetics and Molecular Biology | 2 | 3% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
Agricultural and Biological Sciences | 2 | 3% |
Other | 5 | 7% |
Unknown | 24 | 32% |